Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD.

J Clin Endocrinol Metab. 2009 Jan;94(1):204-12. doi: 10.1210/jc.2008-1456. Epub 2008 Oct 14.

2.

Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.

Sirianni R, Zolea F, Chimento A, Ruggiero C, Cerquetti L, Fallo F, Pilon C, Arnaldi G, Carpinelli G, Stigliano A, Pezzi V.

J Clin Endocrinol Metab. 2012 Dec;97(12):E2238-50. doi: 10.1210/jc.2012-2374. Epub 2012 Oct 16.

PMID:
23074235
3.

Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.

Xu Y, Dong B, Huang J, Kong W, Xue W, Zhu Y, Zhang J, Huang Y.

Oncotarget. 2016 Jan 19;7(3):3233-44. doi: 10.18632/oncotarget.6564.

4.

Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.

Doghman M, Lalli E.

Mol Cell Endocrinol. 2013 Dec 5;381(1-2):66-9. doi: 10.1016/j.mce.2013.07.023. Epub 2013 Jul 30.

PMID:
23906534
5.

The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.

De Martino MC, van Koetsveld PM, Feelders RA, Sprij-Mooij D, Waaijers M, Lamberts SW, de Herder WW, Colao A, Pivonello R, Hofland LJ.

Endocr Relat Cancer. 2012 May 24;19(3):351-64. doi: 10.1530/ERC-11-0270. Print 2012 Jun.

6.

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

Demeure MJ, Bussey KJ, Kirschner LS.

Horm Cancer. 2011 Dec;2(6):385-92. doi: 10.1007/s12672-011-0090-6. Review.

PMID:
22170383
7.

Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.

Hermsen IG, Haak HR, de Krijger RR, Kerkhofs TM, Feelders RA, de Herder WW, Wilmink H, Smit JW, Gelderblom H, de Miranda NF, van Eijk R, van Wezel T, Morreau H.

Eur J Endocrinol. 2013 Jun 1;169(1):51-8. doi: 10.1530/EJE-13-0093. Print 2013 Jul.

8.

Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.

van Koetsveld PM, Vitale G, Feelders RA, Waaijers M, Sprij-Mooij DM, de Krijger RR, Speel EJ, Hofland J, Lamberts SW, de Herder WW, Hofland LJ.

Endocr Relat Cancer. 2013 May 30;20(3):443-54. doi: 10.1530/ERC-12-0217. Print 2013 Jun.

9.

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.

Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.

Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25.

10.

Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.

Gagliano T, Gentilin E, Benfini K, Di Pasquale C, Tassinari M, Falletta S, Feo C, Tagliati F, Uberti ED, Zatelli MC.

Endocrine. 2014 Dec;47(3):943-51. doi: 10.1007/s12020-014-0374-z. Epub 2014 Aug 6.

PMID:
25096913
11.

Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.

Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, Metzger D, Schulte JH, Holst MI, Heukamp LC, Larsson O, Tanaka S, Kawai A, Wardelmann E, Buettner R, Pietsch T, Hartmann W.

J Pathol. 2008 Dec;216(4):428-39. doi: 10.1002/path.2438.

PMID:
18855347
12.

Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.

Hantel C, Jung S, Mussack T, Reincke M, Beuschlein F.

Endocr Relat Cancer. 2014 Apr 28;21(3):383-94. doi: 10.1530/ERC-13-0439. Print 2014 Jun.

13.

Xenograft models for preclinical drug testing: implications for adrenocortical cancer.

Luconi M, Mannelli M.

Mol Cell Endocrinol. 2012 Mar 31;351(1):71-7. doi: 10.1016/j.mce.2011.09.043. Epub 2011 Oct 26. Review.

PMID:
22056412
14.

Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.

Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW.

Lung Cancer. 2008 May;60(2):166-74. Epub 2007 Nov 14.

PMID:
18006183
15.

The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.

Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD.

Horm Cancer. 2014 Aug;5(4):232-9. doi: 10.1007/s12672-014-0182-1. Epub 2014 May 22. Erratum in: Horm Cancer. 2014 Dec;5(6):424. Hasseltine, Elizabeth A [corrected to Hesseltine, Elizabeth A].

16.

Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.

Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.

Clin Cancer Res. 2006 Aug 1;12(15):4755-65.

17.

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.

Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA.

Mol Cancer Ther. 2007 Aug;6(8):2158-67. Epub 2007 Aug 1.

18.

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.

Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ.

Mol Cancer Ther. 2012 Mar;11(3):649-59. doi: 10.1158/1535-7163.MCT-11-0575. Epub 2011 Dec 21.

19.

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.

Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD.

Cancer Chemother Pharmacol. 2010 Mar;65(4):765-73. doi: 10.1007/s00280-009-1083-9. Epub 2009 Aug 2.

20.

Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.

Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M.

Endocrinology. 2015 Nov;156(11):3895-908. doi: 10.1210/en.2015-1367. Epub 2015 Aug 25.

PMID:
26305886

Supplemental Content

Support Center